retatrutide trial results news today Retatrutide, a new weight loss drug not available on the market yet, is showing promising in trials. Dr. LaPook explains it’s doing much more than what current medications can Lilly orforglipron oral GLP-1 phase

In such cases, the appetite-suppressing effects of GLP-1RAs could potentially exacerbate behaviors like dietary restriction and dietary restraint, two behavioral patterns that help sustain eating disorder psychopathology, thus complicating treatment for these disorders

Losing weight while preserving muscle rather than crash dieting produces a far better final shape

Learn about the causes and complications of chronic kidney disease

This series of articles is by no means exhaustive concerning endocrine pathophysiology

Metagenomic and functional analysis of athletes identify an exercise-promoting microbiome

Neurother J Am Soc Exp Neurother 15(1):156175 Garrow TA, Brenner AA, Whitehead VM, Chen XN, Duncan RG, Korenberg JR, Shane B (1993) Cloning of human cDNAs encoding mitochondrial and cytosolic serine hydroxymethyltransferases and chromosomal localization